Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ACADIA PharmaceuticalsMEX:ACAD 75 Cash-to-Debt is 12.95 as of Jun. 2026, which is 8% below its 10-year median of 14.04. GuruFocus rates MEX:ACAD with a GF Score™ of 75/100 and a GF Value™ of MXN356.46 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,393 Biotechnology companies, ACADIA Pharmaceuticals ranks better than 57.65% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. ACADIA Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 12.95.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, ACADIA Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for ACADIA Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
MEX:ACAD'
s Cash-to-Debt Range Over the Past 10 Years
Min: 6.06 Med: 14.04 Max: No Debt
Current: 12.95
During the past 13 years, ACADIA Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 6.06. And the median was 14.04.
MEX:ACAD's Cash-to-Debt is ranked better than 57.65% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs MEX:ACAD: 12.95
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
ACADIA Pharmaceuticals Cash-to-Debt Related Terms
ACADIA Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:ACAD vs PBLS, DYN, EWTX: Cash-to-Debt Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (MEX:ACAD) has a Cash-to-Debt of 12.95 as of Jun. 2026. This is near median its historical median of 14.04. Over the past decade, ACADIA Pharmaceuticals' Cash-to-Debt has ranged from 6.06 to 10,000.00. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #590 out of 1393 companies in the Biotechnology industry, placing it in the top 42.4%.
Is ACADIA Pharmaceuticals' Cash-to-Debt too high?
ACADIA Pharmaceuticals' current Cash-to-Debt of 12.95 is near median its 10-year median of 14.04. Over the past 10 years, this metric has ranged from a low of 6.06 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. ACADIA Pharmaceuticals' value of 12.95 is 84.2% above this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #590 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Cash-to-Debt compare to PBLS and DYN?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #590 out of 1393 companies for Cash-to-Debt. This puts ACADIA Pharmaceuticals in the upper half of its industry. The industry median Cash-to-Debt is 7.03. ACADIA Pharmaceuticals' value of 12.95 is 84.2% above this benchmark. Historically, ACADIA Pharmaceuticals' own Cash-to-Debt has ranged from 6.06 to 10,000.00 over the past decade. While the company's 10-year median is 14.04 vs. the industry median of 7.03, ACADIA Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Cash-to-Debt of 12.95 is 84.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Cash-to-Debt is 12.95, which is near median its own 10-year median of 14.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN356.46, compared to a current price of MXN499.00 — trading 40% above its estimated fair value. The current Cash-to-Debt is 12.95, which is near median its 10-year median of 14.04 and 84.2% above the Biotechnology industry median of 7.03. ACADIA Pharmaceuticals' overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Cash-to-Debt is 12.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN499.00 is trading 40% above its estimated GF Value™ of MXN356.46.
GuruFocus considers ACADIA Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for MEX:ACAD:
Cash-to-Debt: 12.95 (near median its 10-year median of 14.04)
GF Value™: MXN356.46 vs. price of MXN499.00 (40% above fair value)
Industry Position: 84.2% above the Biotechnology median (#590 of 1393)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
75GF Score
Get the complete analysis for MEX:ACAD
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
